Immunic Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Erik Lundgren

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	3.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.7yrs

Jüngste Management Updates

Recent updates

Analyseartikel • Oct 17

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyseartikel • Oct 13

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analyseartikel • Jun 27

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Seeking Alpha • Oct 20

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Immunic (NASDAQ:IMUX) on Thursday said a phase 1b trial of its psoriasis treatment IMU-935 failed to separate from placebo, as measured by a reduction in the severity of the psoriatic lesions in the patients. Shares of the micro-cap clinical-stage biopharma plunged 73.7% to $2.49 after hours. A pre-planned interim analysis of the early-stage trial found a greater decrease than expected in the so-called Psoriasis Area and Severity Index (PASI) in the placebo arm. The PASI is a widely used instrument in psoriasis trials that evaluates and grades the severity of psoriatic lesions and the patient's response to treatment. The trial enrolled a total of 41 patients who were randomized to get 150 mg once-daily and 150 mg twice-daily doses of IMU-935, along with placebo. "At this point, the company only has access to very limited information. The interim analysis only revealed mean values at group-level up to the end of the four-week treatment period. Immunic does not yet have access to unblinded individual patient data," the company said in a statement. IMUX expects to continue IMU-935 development in psoriasis.

Seeking Alpha • Oct 10

Immunic stock gains on $60M oversubscribed PIPE financing

Immunic (NASDAQ:IMUX) shares gained as much as 21% premarket on Monday after the clinical-stage biopharmaceutical company announced a $60M oversubscribed private placement equity financing. The company entered into a securities purchase agreement with select accredited investors and certain existing investors to issue and sell an ~8.69M shares of its common stock at $4.35/share and pre-funded warrants to purchase up to 5,096,552 common shares at $4.34/pre-funded warrant share. The pre-funded warrants will be immediately exercisable at $0.01 per share of common stock and remain exercisable until exercised in full. Gross proceeds from the equity financing is estimated to be around $60M. The financing is expected to close on Oct 12, 2022. Net proceeds will be used to fund Immunic's (IMUX) ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), IMU-935 and IMU-856, and for other general corporate purposes. Proceeds, along with current cash, cash equivalents and marketable securities, is expected to fund operating and capital expenditures into Q4/2024.

Seeking Alpha • Aug 04

Immunic GAAP EPS of -$0.72 in-line

Immunic press release (NASDAQ:IMUX): Q2 GAAP EPS of -$0.72 in-line. Cash and Cash Equivalents as of Q2 $88.1 million.

Analyseartikel • Jul 27

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Geschäftsführer

Erik Lundgren (48 yo)

less than a year

Amtszeit

Mr. Erik Lundgren is Chief Executive Officer of Immunic, Inc. from June 1, 2026. Mr. Lundgren served as Senior Vice President, Commercial Portfolio Organization at Genentech, Inc., a member of the Roche Gr...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jason Tardio	COO & President	2yrs	US$1.20m	0.0092% $ 18.5k
Daniel Vitt	Founder & Director	no data	US$2.30m	0.29% $ 580.0k
Glenn Whaley	Chief Financial Officer	6.3yrs	US$1.06m	0.070% $ 141.4k
Erik Lundgren	Chief Executive Officer	less than a year	keine Daten	keine Daten
Hella Kohlhof	Chief Scientific Officer	9.5yrs	keine Daten	keine Daten
Jessica Breu	Vice President of Investor Relations & Communications	no data	keine Daten	keine Daten
Inderpal Singh	General Counsel	5.1yrs	keine Daten	keine Daten
Patrick Walsh	Chief Business Officer	4.8yrs	keine Daten	keine Daten
Werner Gladdines	Chief Development Officer	2yrs	keine Daten	keine Daten
Michael A. Panzara	Chief Medical Officer	less than a year	keine Daten	keine Daten

3.4yrs

Durchschnittliche Betriebszugehörigkeit

53yo

Durchschnittliches Alter

Erfahrenes Management: IMUXDas Führungsteam des Unternehmens gilt als erfahren (3.4 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Daniel Vitt	Founder & Director	7.3yrs	US$2.30m	0.29% $ 580.0k
Barclay Phillips	Lead Independent Director	6.7yrs	US$171.98k	0.21% $ 415.8k
Michael Bonney	Chair of the Board	less than a year	keine Daten	keine Daten
Tamar Howson	Independent Director	6.8yrs	US$149.82k	0.21% $ 415.8k
Jorg Neermann	Independent Director	7.3yrs	US$156.98k	0.15% $ 296.0k
Paul Utz	Member of Scientific Medical Advisory Board	5.7yrs	keine Daten	keine Daten
Duane Nash	Director	7.5yrs	US$979.88k	0.026% $ 53.3k
Bruce Sands	Member of Scientific Medical Advisory Board	5.7yrs	keine Daten	keine Daten
Fred Lublin	Member of Scientific Medical Advisory Board	5.7yrs	keine Daten	keine Daten
Richard Rudick	Independent Director	3.3yrs	US$149.48k	0.17% $ 341.0k
Jon Congleton	Independent Director	less than a year	keine Daten	keine Daten
Simona Skerjanec	Independent Director	2yrs	US$149.14k	0.15% $ 296.0k

5.7yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrener Vorstand: IMUXDie Vorstandsmitglieder gelten als erfahren (5.7 Jahre durchschnittliche Amtszeit).

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/07/05 08:34
Aktienkurs zum Tagesende	2026/07/02 00:00
Gewinne	2026/03/31
Jährliche Einnahmen	2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Immunic, Inc. wird von 18 Analysten beobachtet. 9 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
George Farmer	BMO Capital Markets Equity Research
William Wood	B. Riley Securities, Inc.
Tyler Bussian	Brookline Capital Markets

Immunic Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Immunic, Inc., Annual General Meeting, Jun 29, 2026

Immunic, Inc. Announces Chief Executive Officer Changes

Immunic, Inc. Appoints Michael W. Bonney as Chair of the Board of Directors, Effective May 16, 2026

Immunic, Inc. Chief Medical Officer Changes, Effective April 24, 2026

Immunic, Inc. Appoints Jon Congleton to Its Board of Directors, Effective March 27, 2026

Immunic, Inc. Plans Transition of Daniel Vitt from CEO

Recent updates

Immunic, Inc., Annual General Meeting, Jun 29, 2026

Immunic, Inc. Announces Chief Executive Officer Changes

Price target decreased by 10% to US$44.67

Immunic, Inc. Appoints Michael W. Bonney as Chair of the Board of Directors, Effective May 16, 2026

Immunic, Inc. Chief Medical Officer Changes, Effective April 24, 2026

Immunic, Inc. Appoints Jon Congleton to Its Board of Directors, Effective March 27, 2026

Price target increased by 11% to US$5.00

No longer forecast to breakeven

New major risk - Negative shareholders equity

Immunic, Inc. announced that it has received $200.010837 million in funding from a group of investors

Immunic, Inc. Prioritizes Completion of the Ongoing Phase 3 Ensure Clinical Trials and Initiation of A Phase 3 Clinical Program in Primary Progressive Multiple Sclerosis

Immunic, Inc. announced that it expects to receive $200 million in funding from a group of investors

Immunic, Inc. Plans Transition of Daniel Vitt from CEO

New minor risk - Share price stability

Immunic to Present Additional Phase 2 Calliper Trial Data Foridofludimus Calcium At the Actrims Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Nasdaq Grants Immunic, Inc. an Additional 180-Day Grace Period to Regain Compliance with the Bid Price Rule

Immunic, Inc.'s Subsidiary Gliomic Therapeutics Inc. Announces Executive Appointments, Effective January 1, 2026

Forecast to breakeven in 2028

New major risk - Shareholder dilution

New minor risk - Profitability

We're A Little Worried About Immunic's (NASDAQ:IMUX) Cash Burn Rate

Price target decreased by 11% to US$6.83

Immunic, Inc. Presents Key Vidofludimus Calcium Data At the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Immunic, Inc. Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

New major risk - Financial position

No longer forecast to breakeven

Immunic, Inc. Receives Notice of Nasdaq Non-Compliance with Minimum Bid Price Requirement

Immunic, Inc. Reports New, Positive Long-Term Open-Label Extension Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Independent Director recently bought US$100k worth of stock

Immunic, Inc. Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 Calliper Trial in Progressive MS

Price target decreased by 8.3% to US$12.55

Immunic, Inc. has announced a Derivatives Offering.

New major risk - Negative shareholders equity

New minor risk - Share price stability

Immunic, Inc. Announces Positive Data from Phase 2 Calliper Trial of Nurr1 (Nurr1) Activator,Idofludimus Calcium (Imu-838) in Patients with Progressive Multiple Sclerosis

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Immunic, Inc., Annual General Meeting, Jun 04, 2025

Immunic, Inc. has completed a Follow-on Equity Offering in the amount of $5.1 million.

Immunic, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Price target increased by 7.0% to US$13.12

Immunic, Inc.'s Oral IMU-856 Demonstrates Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

New minor risk - Market cap size

Independent Director recently bought US$100k worth of stock

No longer forecast to breakeven

Immunic, Inc. to Report Q3, 2024 Results on Nov 07, 2024

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Immunic, Inc. Announces Positive Outcome of Interim Analysis of Phase 3 Ensure Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial ofidofludimus Calcium in Patients with Post COVID Syndrome

Price target decreased by 13% to US$11.90

New major risk - Financial position

New minor risk - Share price stability

New minor risk - Profitability

No longer forecast to breakeven

New major risk - Financial position

Immunic, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Immunic, Inc. Appoints Simona Skerjanec as Member of the Board

Immunic, Inc. Appoints Jason Tardio as Chief Operating Officer and President

New minor risk - Profitability

No longer forecast to breakeven

Immunic, Inc. to Report Q1, 2024 Results on May 08, 2024

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Immunic, Inc., Annual General Meeting, Jun 11, 2024

Price target decreased by 32% to US$9.00

Immunic, Inc. to Report Fiscal Year 2023 Results on Feb 22, 2024

New major risk - Shareholder dilution

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Immunic, Inc. announced that it expects to receive $240 million in funding from BVF Partners L.P., Avidity Partners, LLC, Janus Henderson Investors, Soleus Capital, RTW Investments, LP, Adage Capital Management, L.P.

Forecast to breakeven in 2026